ID: ALA1204097

Max Phase: Preclinical

Molecular Formula: C27H30ClFN4O4

Molecular Weight: 492.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(O)c(C(=O)c2ccc(NC[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl

Standard InChI:  InChI=1S/C27H29FN4O4.ClH/c1-36-23-9-8-22(33)24(25(23)28)26(34)17-4-6-20(7-5-17)31-15-19-3-2-12-30-16-21(19)32-27(35)18-10-13-29-14-11-18;/h4-11,13-14,19,21,30-31,33H,2-3,12,15-16H2,1H3,(H,32,35);1H/t19-,21?;/m0./s1

Standard InChI Key:  XWUPMAAGDFVXIT-AUFHPKEVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.55

Molecular Weight (Monoisotopic): 492.2173

AlogP: 3.38

#Rotatable Bonds: 8

Polar Surface Area: 112.58

Molecular Species: BASE

HBA: 7

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 6.89

CX Basic pKa: 9.82

CX LogP: 1.98

CX LogD: 1.90

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.36

Np Likeness Score: -0.37

References

1. Breitenlechner CB, Wegge T, Berillon L, Graul K, Marzenell K, Friebe WG, Thomas U, Schumacher R, Huber R, Engh RA, Masjost B..  (2004)  Structure-based optimization of novel azepane derivatives as PKB inhibitors.,  47  (6): [PMID:14998327] [10.1021/jm0310479]

Source

Source(1):

• Scientific Literature